Evidence map›Paper›PMID 42275616›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2026

Brain Immune Cell Composition in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy After Natalizumab: An Immunohistochemical Cohort Study.

Benita-Sophie Raabe, Lidia Stork, Adriane Kutllovci, Susan E Goelz, Imke Metz

Abstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Benita-Sophie RaabeInstitute of Neuropathology, University Medical Center Goettingen, Germany.
Lidia StorkInstitute of Neuropathology, University Medical Center Goettingen, Germany.
Adriane KutllovciInstitute of Neuropathology, University Medical Center Goettingen, Germany.
Susan E GoelzBiogen, Cambridge, MA; and.
Imke MetzInstitute of Neuropathology, University Medical Center Goettingen, Germany.ORCID 0000-0002-6571-7630

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesNatalizumab therapy in multiple sclerosis (MS) increases the risk of progressive multifocal leukoencephalopathy (PML) and may alter lymphocyte distribution within the CNS. Tissue-resident memory CD8

methodsFluorescence immunohistochemistry was performed on brain biopsies and autopsies from patients with MS (n = 34) and those with PML (n = 27) with and without prior natalizumab exposure and from healthy controls (n = 11). The analysis included CD103+ (T

resultsT DISCUSSION: T

Indexed as

BrainCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesImmunologic FactorsLeukoencephalopathy, Progressive MultifocalMultiple SclerosisNatalizumabAdultCohort StudiesDendritic CellsFemaleHumansImmunohistochemistryMaleMiddle AgedImmunologic FactorsNatalizumab

Identifiers

PMID42275616
PMCPMC13262666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.